{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-024277","form_type":"8-K","ticker":"PPCB","cik":"0001517681","company_name":"Propanc Biopharma, Inc.","filed_at":"2023-07-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.170740+00:00","generated_at":"2026-06-13T09:25:57.144674+00:00","sec_items":["1.01","2.03","3.02","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Propanc Biopharma secures $65K convertible note and AU$230K loan; issues warrant for 15M shares","bullets":["Entered securities purchase agreement with 1800 Diagonal Lending LLC for $65,000 convertible note at 8% interest, convertible at 65% of market price.","Loan agreement with institutional investor for AU$230,000 at 10% interest, 3-year term; issued warrant for 15M shares at $0.01.","Proceeds used to repay ~$143,000 convertible note in default; remaining for working capital.","Convertible note maturity June 29, 2024; prepayment premiums range from 110% to 129%."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-024277","json":"https://secwatch.observer/filing/0001493152-23-024277.json","markdown":"https://secwatch.observer/filing/0001493152-23-024277.md","text":"https://secwatch.observer/filing/0001493152-23-024277.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1517681/000149315223024277/0001493152-23-024277-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1517681/000149315223024277/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T09:25:57.144674+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3c11663aa3938a6848f5f809382b50f862103dd6","claim":"Propanc Biopharma, Inc. incurred convertible notes of $65,000 with June Investor at 8% per annum maturing June 29, 2024.","evidence_excerpt":"On June 29, 2023, Propanc Biopharma, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an investor (the “June Investor”), which closed on July 6, 2023, pursuant to which the June Investor purchased a convertible promissory note (the “June Note”) from the Company in the aggregate principal amount of $65,000","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1517681/000149315223024277/0001493152-23-024277-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"$65,000"},{"label":"Counterparty","value":"June Investor"},{"label":"Rate","value":"8% per annum"},{"label":"Maturity","value":"June 29, 2024"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"7c58c2b7545a60a3ced9ab2e6215245ac938c8f4","claim":"Propanc Biopharma, Inc. incurred loan of AU$230,000 with July Investor at 10% maturing July 5, 2026.","evidence_excerpt":"On July 5, 2023, the Company and an institutional investor (the “July Investor”) entered into a letter agreement (the “Loan Agreement”), pursuant to which the July Investor loaned the Company an aggregate of AU$230,000","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1517681/000149315223024277/0001493152-23-024277-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"loan"},{"label":"Principal","value":"AU$230,000"},{"label":"Counterparty","value":"July Investor"},{"label":"Rate","value":"10%"},{"label":"Maturity","value":"July 5, 2026"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"d73aed9a3db16ba0a6c443fad4792f96645ec041","claim":"Propanc Biopharma, Inc. entered into Purchase Agreement with June Investor valued at $65,000 (effective 2023-06-29).","evidence_excerpt":"On June 29, 2023, Propanc Biopharma, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an investor (the “June Investor”), which closed on July 6, 2023, pursuant to which the June Investor purchased a convertible promissory note (the “June Note”) from the Company in the aggregate principal amount of $65,000","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1517681/000149315223024277/0001493152-23-024277-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"June Investor"},{"label":"Value","value":"$65,000"},{"label":"Effective","value":"2023-06-29"}],"fact_type":"material_agreement"},{"claim_id":"fb8841f93de215b6f3fd2d670387d488b5e4931f","claim":"Propanc Biopharma, Inc. entered into Loan Agreement with July Investor valued at AU$230,000 (effective 2023-07-05).","evidence_excerpt":"On July 5, 2023, the Company and an institutional investor (the “July Investor”) entered into a letter agreement (the “Loan Agreement”), pursuant to which the July Investor loaned the Company an aggregate of AU$230,000.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1517681/000149315223024277/0001493152-23-024277-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"July Investor"},{"label":"Value","value":"AU$230,000"},{"label":"Effective","value":"2023-07-05"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}